ETFS Holding Actavis Inc

 
ETF Quotes for ETFS Holding Actavis Inc top ^
  • Holdings: Johnson & Johnson , Pfizer Inc , Merck & Co Inc , Actavis PLC , Bristol-Myers Squibb Company ,
  • Morningstar Rating: 4 Stars
Sign-up for ihe investment picks
  • Holdings: Medivation Inc , Idexx Laboratories , Cooper Companies , Actavis PLC , Illumina Inc ,
  • Morningstar Rating: 2 Stars
Sign-up for pth investment picks
  • Holdings: Actavis PLC , Lam Research Corp , SanDisk Corp , Celgene Corp , Gilead Sciences Inc ,
  • Morningstar Rating: 4 Stars
Sign-up for fwdd investment picks
  • Holdings: Valeant Pharmaceuticals International Inc , Micron Technology Inc , Constellation Brands Inc Class A , Houghton Mifflin Harcourt Company , Actavis PLC ,
Sign-up for alfa investment picks

 
News Articles for Actavis Inc top ^
DUBLIN , April 15, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Mylan Inc. and Famy Care Ltd.
Sign-up for Actavis Announces Agreement Related to Generess® FE Patent Challenge Litigation investment picks
DUBLIN and NEW YORK , April 17, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) and Forest Laboratories, Inc. (NYSE: FRX) today announced that they have each received a request for additional information from the Federal Trade Commission ("FTC") in connection with Actavis' pending acquisition of Forest.
Sign-up for Actavis and Forest Laboratories Receive FTC Second Request Under Hart-Scott-Rodino investment picks
DUBLIN , April 21, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that G.
Sign-up for Actavis Announces Departure of G. Frederick Wilkinson, President, Actavis Global R&D investment picks
DUBLIN , April 24, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Pfizer, Inc. to settle all outstanding patent litigation related to Actavis' generic version of Celebrex ® (celecoxib) 50 mg, 100 mg, 200 mg and 400 mg capsules.
Sign-up for Actavis Announces Celebrex® Patent Challenge Settlement investment picks
DUBLIN , April 28, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that its subsidiary, Watson Laboratories, Inc., has filed suit against the U.S. Food and Drug Administration (FDA) challenging the Agency's decision regarding its entitlement to shared 180-day marketing exclusivity for its generic version of Celebrex ® (celecoxib) 50 mg, 100 mg, 200 mg and 400 mg capsules.
Sign-up for Actavis Sues FDA Regarding Delay of Generic Celebrex® Approval investment picks
- First Quarter 2014 GAAP Earnings Per Diluted Share of $0.55 - - 86% Increase in First Quarter 2014 Adjusted EBITDA to $860 million - DUBLIN , April 30, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today reported net revenue increased 40 percent to $2.66 billion for the first quarter ended March 31, 2014 , compared to $1.90 billion in the first quarter 2013.
Sign-up for Actavis Net Revenue Increases 40% to $2.66 Billion in First Quarter 2014; Non-GAAP EPS Increases 75% to $3.49 investment picks
DUBLIN , May 7, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has launched a generic version of Boehringer Ingelheim's Catapres-TTS ® (Clonidine Transdermal System, USP, 0.1 mg/day, 0.2 mg/day, and 0.3 mg/day for one week), following the receipt of final approval on its Abbreviated New Drug Application from the U.S. Food and Drug Administration.
Sign-up for Actavis Launches Generic Version of Catapres-TTS® investment picks
-- Companies Schedule Shareholder Meetings for June 17, 2014 --
Sign-up for Actavis and Forest Announce Effectiveness of Registration Statement on Form S-4 investment picks
DUBLIN , May 13, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for a generic version of Mallinckrodt Inc.'s Exalgo ® (Hydromorphone Hydrochloride Extended-release Tablets 8 mg, 12 mg and 16 mg). Actavis intends to begin shipping its product shortly and believes that, under applicable Hatch Waxman rules, it may be entitled to marketing exclusivity.
Sign-up for Actavis Receives Final Approval for Generic Version of Exalgo® investment picks
DUBLIN , May 13, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) , a leading global specialty pharmaceutical company, today announced that Paul Bisaro , Chairman and CEO of Actavis, will provide an overview and update of the Company's business at the Sanford C.
Sign-up for Actavis to Present at Sanford C. Bernstein Thirtieth Annual Strategic Decisions Conference 2014 investment picks
2014/5/12
Valeant Pharmaceuticals Enters Into Patent Settlement Agreements With Actavis Canada NewsWire LAVAL, Quebec , May 12, 2014 /CNW/ - Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that certain of its subsidiaries have entered into settlement agreements with affiliates of Actavis plc related to Actavis' generic versions of Acanya® Gel, 1.2%/2.5%, and Tiazac ® XC.
Sign-up for Valeant Pharmaceuticals Enters Into Patent Settlement Agreements With Actavis investment picks
2014/5/12
LAVAL, Quebec , May 12, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that certain of its subsidiaries have entered into settlement agreements with affiliates of Actavis plc related to Actavis' generic versions of Acanya® Gel, 1.2%/2.5%, and Tiazac ® XC.
Sign-up for Valeant Pharmaceuticals Enters Into Patent Settlement Agreements With Actavis investment picks
DUBLIN , May 12, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Valeant Pharmaceuticals International to settle all outstanding patent litigation related to Actavis' generic version of Acanya ® (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/2.5%. Acanya ® Gel is a lincosamide antibiotic and benzoyl peroxide indicated for the topical treatment of acne vulgaris.
Sign-up for Actavis Announces Acanya® Gel Patent Challenge Settlement investment picks
- Paul Bisaro to Assume Newly Created Role as Executive Chairman - - Brent Saunders to be Named CEO and President - - Robert Stewart to be Named COO - - Bill Meury to be Named EVP Commercial, North American Brands - - David Buchen to be Named EVP Commercial, North American Generics and International - DUBLIN , May 14, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced the proposed senior management team that will lead the specialty pharmaceutical company pending the successful close of the acquisition of Forest Laboratories, Inc., which is anticipated at mid-year.
Sign-up for Actavis Announces Proposed Senior Leadership Team Effective Following Completion of Forest Laboratories Acquisition investment picks
DUBLIN , May 22, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that, subject to the close of its pending acquisition (the "Acquisition") of Forest Laboratories, Inc. (NYSE: FRX) , it is offering to guarantee certain of Forest's outstanding debt securities in exchange for the elimination of the existing registration rights obligations with respect to those outstanding debt securities.
Sign-up for Actavis Offers to Guarantee Certain Forest Laboratories Senior Notes in connection with Forest Consent Solicitations investment picks
DUBLIN , May 21, 2014 /PRNewswire/ -- Actavis plc (NYSE:ACT) , a leading global specialty pharmaceutical company, today announced that Paul Bisaro , Chairman and CEO of Actavis, will provide an overview and update of the Company's business at the Goldman Sachs 35 th Annual Global Healthcare Conference 2014 in Rancho Palos Verdes, California .
Sign-up for Actavis to Present at Goldman Sachs 35th Annual Global Healthcare Conference 2014 investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

ETFS Holding Actavis Inc
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: ETFS Holding Abiomed, Inc.  |  Next: ETFS Holding Activision Blizzard, Inc.